vs
弗雷斯特研究公司（FORR）与Stoke Therapeutics, Inc.（STOK）财务数据对比。点击上方公司名可切换其他公司
Stoke Therapeutics, Inc.的季度营收约是弗雷斯特研究公司的1.6倍（$158.6M vs $101.1M），Stoke Therapeutics, Inc.净利率更高（71.2% vs -33.5%，领先104.7%），Stoke Therapeutics, Inc.同比增速更快（3661.1% vs -6.5%），Stoke Therapeutics, Inc.自由现金流更多（$131.7M vs $-4.3M）
福雷斯特研究公司是一家全球领先的研究咨询机构，主营业务涵盖行业研究、管理咨询与行业峰会举办，客户群体包括全球大型企业、科技公司与消费领域领军企业，公司总部位于美国马萨诸塞州剑桥市。
Stoke Therapeutics是一家临床阶段生物技术企业，专注开发靶向RNA的创新疗法，用于治疗严重罕见遗传病。其领先候选药物针对德拉韦综合征等罕见癫痫及其他单基因神经系统疾病，满足全球患者未被满足的医疗需求。
FORR vs STOK — 直观对比
营收规模更大
STOK
是对方的1.6倍
$101.1M
营收增速更快
STOK
高出3667.6%
-6.5%
净利率更高
STOK
高出104.7%
-33.5%
自由现金流更多
STOK
多$136.0M
$-4.3M
损益表 — Q4 FY2025 vs Q1 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $101.1M | $158.6M |
| 净利润 | $-33.9M | $112.9M |
| 毛利率 | 56.7% | — |
| 营业利润率 | -36.6% | 70.2% |
| 净利率 | -33.5% | 71.2% |
| 营收同比 | -6.5% | 3661.1% |
| 净利润同比 | -7941.4% | 528.0% |
| 每股收益（稀释后） | $-1.75 | $1.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FORRSTOK
| Q4 25 | $101.1M | — | ||
| Q3 25 | $94.3M | — | ||
| Q2 25 | $111.7M | — | ||
| Q1 25 | $89.9M | $158.6M | ||
| Q4 24 | $108.0M | $22.6M | ||
| Q3 24 | $102.5M | — | ||
| Q2 24 | $121.8M | — | ||
| Q1 24 | $100.1M | — |
净利润FORRSTOK
| Q4 25 | $-33.9M | — | ||
| Q3 25 | $-2.1M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $-87.3M | $112.9M | ||
| Q4 24 | $432.0K | $-10.5M | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-6.7M | — |
毛利率FORRSTOK
| Q4 25 | 56.7% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 55.5% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 58.8% | — | ||
| Q3 24 | 60.5% | — | ||
| Q2 24 | 57.3% | — | ||
| Q1 24 | 54.9% | — |
营业利润率FORRSTOK
| Q4 25 | -36.6% | — | ||
| Q3 25 | 4.7% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | -97.5% | 70.2% | ||
| Q4 24 | -0.5% | -60.4% | ||
| Q3 24 | -0.7% | — | ||
| Q2 24 | 9.3% | — | ||
| Q1 24 | -9.3% | — |
净利率FORRSTOK
| Q4 25 | -33.5% | — | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | -97.1% | 71.2% | ||
| Q4 24 | 0.4% | -46.4% | ||
| Q3 24 | -5.7% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | -6.7% | — |
每股收益（稀释后）FORRSTOK
| Q4 25 | $-1.75 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $0.20 | — | ||
| Q1 25 | $-4.62 | $1.90 | ||
| Q4 24 | $0.02 | $-0.15 | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $0.33 | — | ||
| Q1 24 | $-0.35 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $274.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $126.5M | $350.1M |
| 总资产 | $404.0M | $406.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FORRSTOK
| Q4 25 | $63.3M | — | ||
| Q3 25 | $65.1M | — | ||
| Q2 25 | $67.8M | — | ||
| Q1 25 | $75.6M | $274.8M | ||
| Q4 24 | $56.1M | $128.0M | ||
| Q3 24 | $62.8M | — | ||
| Q2 24 | $58.9M | — | ||
| Q1 24 | $61.4M | — |
股东权益FORRSTOK
| Q4 25 | $126.5M | — | ||
| Q3 25 | $157.7M | — | ||
| Q2 25 | $159.5M | — | ||
| Q1 25 | $147.4M | $350.1M | ||
| Q4 24 | $229.5M | $229.0M | ||
| Q3 24 | $234.3M | — | ||
| Q2 24 | $237.1M | — | ||
| Q1 24 | $230.9M | — |
总资产FORRSTOK
| Q4 25 | $404.0M | — | ||
| Q3 25 | $414.2M | — | ||
| Q2 25 | $436.0M | — | ||
| Q1 25 | $439.8M | $406.9M | ||
| Q4 24 | $503.9M | $271.6M | ||
| Q3 24 | $505.3M | — | ||
| Q2 24 | $524.2M | — | ||
| Q1 24 | $555.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.2M | $131.8M |
| 自由现金流经营现金流 - 资本支出 | $-4.3M | $131.7M |
| 自由现金流率自由现金流/营收 | -4.2% | 83.0% |
| 资本支出强度资本支出/营收 | 1.1% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 1.17× |
| 过去12个月自由现金流最近4个季度 | $18.1M | — |
8季度趋势，按日历期对齐
经营现金流FORRSTOK
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $26.7M | $131.8M | ||
| Q4 24 | $-1.8M | $-23.2M | ||
| Q3 24 | $264.0K | — | ||
| Q2 24 | $-2.9M | — | ||
| Q1 24 | $611.0K | — |
自由现金流FORRSTOK
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $524.0K | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $26.1M | $131.7M | ||
| Q4 24 | $-2.5M | $-23.2M | ||
| Q3 24 | $-223.0K | — | ||
| Q2 24 | $-3.7M | — | ||
| Q1 24 | $-815.0K | — |
自由现金流率FORRSTOK
| Q4 25 | -4.2% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -3.8% | — | ||
| Q1 25 | 29.0% | 83.0% | ||
| Q4 24 | -2.3% | -102.7% | ||
| Q3 24 | -0.2% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | -0.8% | — |
资本支出强度FORRSTOK
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.7% | — | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | 0.1% | ||
| Q4 24 | 0.6% | 0.2% | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.4% | — |
现金转化率FORRSTOK
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
STOK
暂无分部数据
